# Nasus Pharma Ltd. (NSRX)

> Source: Nexqual · https://nexqual.com/NSRX · data as of 2026-10-15 18:58 UTC · cite as "Nexqual, Nasus Pharma Ltd. (NSRX), nexqual.com/NSRX" · informational, not investment advice.

**Price:** USD 3.17 (-0.47% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 3.18 · day 3.05–3.18 · 52w 1.98–9.5 · market cap $37.1M · ASE

## Key facts
- Analysts: Strong Buy (mean 1.00 on a 1–5 scale) (2 analysts), mean target USD 19.67 (range 18–22).
- Total return with dividends: 1Y -60.0% vs S&P 500 +18.1%; 5Y -60.9% vs S&P 500 +85.1%.

## Analysts
Consensus Strong Buy (mean 1.00 on a 1–5 scale), 2 analysts; mean target USD 19.67 (low 18, high 22).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2025-08-11) |
|---|---|---|
| Total return | -60.0% | -60.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -60.2% | -54.9% |
| Volatility (annualized) | 104.4% | 95.0% |
| Max drawdown | -78.0% (Dec 2025→Mar 2026) | -73.0% (Aug 2025→Apr 2026) |

## Peers (Drug Manufacturers - General)
OGN (Organon & Co.) USD 13.76 -0.07% · GRFS (Grifols, S.A.) USD 7.54 +5.16% · BIIB (Biogen Inc.) USD 235.35 +2.82% · SNY (Sanofi) USD 40.29 +2.99% · GSK (GSK plc) USD 49.02 +5.94% · BMY (Bristol-Myers Squibb Company) USD 60.57 +6.88%

## More
Full page: https://nexqual.com/NSRX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt